The brief negative symptom scale (BNSS): Sensitivity to treatment effects

Kirkpatrick, Brian; Saoud, Jay; Strauss, Gregory P.; Ahmed, Anthony O.; Tatsumi, Kazunori; Opler, Mark; Luthringer, R.; Davidson, Michael

doi:10.1016/j.schres.2017.11.031

Cited by 22 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BNSS has substantial advantages with respect to PANSS for the identification of the experiential domain (including avolition, asociality, and anhedonia) and in subjects with predominant negative symptoms [74]. Preliminary evidence indicates that BNSS is also sensitive to change [147].…”

Section: Second Generation Scalesmentioning

confidence: 99%

EPA guidance on assessment of negative symptoms in schizophrenia

et al. 2021

View full text Add to dashboard Cite

Background. During the last decades, a renewed interest for negative symptoms (NS) was brought about by the increased awareness that they interfere severely with real-life functioning, particularly when they are primary and persistent. Methods. In this guidance paper, we provide a systematic review of the evidence and elaborate several recommendations for the conceptualization and assessment of NS in clinical trials and practice. Results. Expert consensus and systematic reviews have provided guidance for the optimal assessment of primary and persistent negative symptoms; second-generation rating scales, which provide a better assessment of the experiential domains, are available; however, NS are still poorly assessed both in research and clinical settings. This European Psychiatric Association (EPA) guidance recommends the use of persistent negative symptoms (PNS) construct in the context of clinical trials and highlights the need for further efforts to make the definition of PNS consistent across studies in order to exclude as much as possible secondary negative symptoms. We also encourage clinicians to use secondgeneration scales, at least to complement first-generation ones. The EPA guidance further recommends the evidence-based exclusion of several items included in first-generation scales from any NS summary or factor score to improve NS measurement in research and clinical settings. Self-rated instruments are suggested to further complement observer-rated scales in NS assessment. Several recommendations are provided for the identification of secondary negative symptoms in clinical settings. Conclusions. The dissemination of this guidance paper may promote the development of national guidelines on negative symptom assessment and ultimately improve the care of people with schizophrenia.

show abstract

Section: Second Generation Scalesmentioning

confidence: 99%

EPA guidance on assessment of negative symptoms in schizophrenia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A blinding procedure was used: participants' interviews were recorded and each video or sound recording was evaluated at the end of the study by two independent evaluators who were unaware of the recordings' assessment time. The BNSS possesses excellent internal, convergent and discriminant validity [28], excellent test-retest and interrater reliability [27], and good sensitivity to change [29].…”

Section: Traditional Evaluation (Primary Outcomes)mentioning

confidence: 99%

Idiographic analyses of motivation and related processes in participants with schizophrenia following a therapeutic intervention for negative symptoms

et al. 2020

View full text Add to dashboard Cite

Background Motivational negative symptoms hinder quality of life and daily functioning of individuals with schizophrenia spectrum disorders. A recently developed intervention, Switch, has shown promising effects on negative symptoms and functional outcomes. Switch targets multiple cognitive, emotional and behavioural processes associated with motivation and goal directed behaviours. We aimed to investigate its effects on motivation and associated processes in a naturalistic setting, and to explore the dynamics between the processes. Methods We used a single case approach (n = 3), with a pre-post and follow-up assessment design, which also included ambulatory assessments (experience sampling method, ESM; and step count). We computed autoregressive lag 1 models to evaluate the effects of the intervention on daily motivation levels and related processes, descriptive pie-charts, and vector autoregressive modelling to reveal the dynamics of the processes over time. Results The intervention was beneficial for each participant according to traditional evaluations of motivational negative symptoms, apathy, daily functioning and quality of life. The effects on the ESM variables revealed distinct outcomes for each individual. The dynamics between the various processes differed between participants, and fluctuated within participants (when comparing baseline, intervention phase, and follow-up). Conclusions This study used an innovative approach to look at the effectiveness of an intervention. The intervention seems to lead to meaningful improvements in motivational negative symptoms and functional outcomes. The mechanisms of change need to be further investigated. Trial registration number ClinicalTrials.gov, NCT04325100. Registered 27 March 27, 2020 -retrospectively registered. Reporting Guidelines from the Transparent Reporting of Evaluations with Non-randomized Designs (TREND) statement were followed.

show abstract

“…A blinding procedure was used: participants' interviews were recorded and each video or sound recording was evaluated at the end of the study by two independent evaluators who were unaware of the recordings' assessment time. The BNSS possesses excellent internal, convergent and discriminant validity [27], excellent test-retest and interrater reliability [26], and good sensitivity to change [28]. [30].…”

Section: Traditional Evaluation (Primary Outcomes)mentioning

confidence: 99%

Idiographic analyses of motivation and related processes in participants with schizophrenia following a therapeutic intervention for negative symptoms

Thonon

Aubel

Lafit

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Motivational negative symptoms hinder quality of life and daily functioning of individuals with schizophrenia spectrum disorders. A recently developed intervention, Switch, has shown promising effects on negative symptoms and functional outcomes. Switch targets multiple cognitive, emotional and behavioural processes associated with motivation and goal directed behaviours. We aimed to investigate its effects on motivation and associated processes and explore the dynamics between the processes. Methods We used a single case approach (n = 3), with a pre-post and follow-up assessment design, which also included ambulatory assessments (experience sampling method, ESM; and step count). We computed autoregressive lag 1 models to evaluate the effects of the intervention on daily motivation levels and related processes, descriptive pie-charts, and vector autoregressive modelling to reveal the dynamics of the processes over time. Results The intervention was beneficial for each participant according to traditional evaluations of motivational negative symptoms, apathy, daily functioning and quality of life. The effects on the ESM variables revealed distinct outcomes for each individual. The dynamics between the various processes differed between participants, and fluctuated within participants (when comparing baseline, intervention phase, and follow-up). Conclusions This study used an innovative approach to look at the efficacy of an intervention. The intervention seems to lead to significant improvements. The mechanisms of change need to be further investigated. Trial registration number: ClinicalTrials.gov, NCT04325100. Registered 27 March 27, 2020 -retrospectively registered, https://www.clinicaltrials.gov/ct2/show/NCT04325100 Reporting: Guidelines from the Transparent Reporting of Evaluations with Non-randomized Designs (TREND) statement [1] were followed.

show abstract

The brief negative symptom scale (BNSS): Sensitivity to treatment effects

Cited by 22 publications

References 27 publications

EPA guidance on assessment of negative symptoms in schizophrenia

EPA guidance on assessment of negative symptoms in schizophrenia

Idiographic analyses of motivation and related processes in participants with schizophrenia following a therapeutic intervention for negative symptoms

Idiographic analyses of motivation and related processes in participants with schizophrenia following a therapeutic intervention for negative symptoms

Contact Info

Product

Resources

About